The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel

Abstract Introduction Psoriasis is a chronic inflammatory condition affecting the skin, joints, and several other organ systems with significant disease burden. Bimekizumab is the first monoclonal antibody targeting both interleukin (IL)-17A and interleukin-17F and has demonstrated efficacy for trea...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Joshua Burshtein, Milaan Shah, Danny Zakria, Benjamin Lockshin, Jeff Crowley, Joseph F. Merola, Ken Gordon, Mona Shahriari, Neil J. Korman, Raj Chovatiya, Robert Kalb, Mark Lebwohl
Format:	Artigo
Jezik:	Inglês
Izdano:	Adis, Springer Healthcare 2024-02-01
Serija:	Dermatology and Therapy
Teme:	Psoriasis IL-17 Interleukin Biologic Bimekizumab Treatment
Online dostop:	https://doi.org/10.1007/s13555-024-01099-y
Oznake:	Označite Brez oznak, prvi označite!